Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

MLA

Pratley, Richard E., et al. “Cardiovascular Safety and Lower Severe Hypoglycaemia of Insulin Degludec versus Insulin Glargine U100 in Patients with Type 2 Diabetes Aged 65 Years or Older: Results from DEVOTE (DEVOTE 7).” Diabetes, Obesity & Metabolism, vol. 21, no. 7, July 2019, pp. 1625–33. EBSCOhost, https://doi.org/10.1111/dom.13699.

APA

Pratley, R. E., Emerson, S. S., Franek, E., Gilbert, M. P., Marso, S. P., McGuire, D. K., Pieber, T. R., Zinman, B., Hansen, C. T., Hansen, M. V., Mark, T., Moses, A. C., & Buse, J. B. (2019). Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, Obesity & Metabolism, 21(7), 1625–1633. https://doi.org/10.1111/dom.13699

Chicago

Pratley, Richard E, Scott S Emerson, Edward Franek, Matthew P Gilbert, Steven P Marso, Darren K McGuire, Thomas R Pieber, et al. 2019. “Cardiovascular Safety and Lower Severe Hypoglycaemia of Insulin Degludec versus Insulin Glargine U100 in Patients with Type 2 Diabetes Aged 65 Years or Older: Results from DEVOTE (DEVOTE 7).” Diabetes, Obesity & Metabolism 21 (7): 1625–33. doi:10.1111/dom.13699.